Metabolic dysfunction-associated steatotic liver disease in adults

被引:1
作者
Huang, Daniel Q. [1 ,2 ]
Wong, Vincent W. S. [3 ]
Rinella, Mary E. [4 ]
Boursier, Jerome [5 ,6 ]
Lazarus, Jeffrey V. [7 ,8 ,9 ]
Yki-Jarvinen, Hannele [10 ,11 ,12 ]
Loomba, Rohit [13 ,14 ]
机构
[1] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore
[2] Natl Univ Hlth Syst, Dept Med, Div Gastroenterol & Hepatol, Singapore, Singapore
[3] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China
[4] Univ Chicago, Pritzker Sch Med, Chicago, IL USA
[5] CHU Angers, Serv Hepato Gastroenterol & Oncol Digest, F-49100 Angers, France
[6] Univ Angers, Lab Hifih, SFR ICAT 4208, Angers, France
[7] Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain
[8] Univ Barcelona, Fac Med & Hlth Sci, Barcelona, Spain
[9] CUNY, Grad Sch Publ Hlth & Hlth Policy, New York, NY USA
[10] Univ Helsinki, Dept Med, Helsinki, Finland
[11] Helsinki Univ Hosp, Helsinki, Finland
[12] Minerva Fdn, Inst Med Res, Helsinki, Finland
[13] Univ Calif San Diego, MASLD Res Ctr, Div Gastroenterol & Hepatol, San Diego, CA 92093 USA
[14] Univ Calif San Diego, Div Epidemiol, Dept Family Med & Publ Hlth, San Diego, CA 92093 USA
来源
NATURE REVIEWS DISEASE PRIMERS | 2025年 / 11卷 / 01期
关键词
NONALCOHOLIC FATTY LIVER; QUALITY-OF-LIFE; MAGNETIC-RESONANCE ELASTOGRAPHY; DELPHI CONSENSUS STATEMENT; EXOME-WIDE ASSOCIATION; WEIGHT-LOSS; INSULIN-RESISTANCE; BARIATRIC SURGERY; VITAMIN-E; CONFERS SUSCEPTIBILITY;
D O I
10.1038/s41572-025-00599-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the umbrella term that comprises metabolic dysfunction-associated steatotic liver, or isolated hepatic steatosis, through to metabolic dysfunction-associated steatohepatitis, the progressive necroinflammatory disease form that can progress to fibrosis, cirrhosis and hepatocellular carcinoma. MASLD is estimated to affect more than one-third of adults worldwide. MASLD is closely associated with insulin resistance, obesity, gut microbial dysbiosis and genetic risk factors. The obesity epidemic and the growing prevalence of type 2 diabetes mellitus greatly contribute to the increasing burden of MASLD. The treatment and prevention of major metabolic comorbidities such as type 2 diabetes mellitus and obesity will probably slow the growth of MASLD. In 2023, the field decided on a new nomenclature and agreed on a set of research and action priorities, and in 2024, the US FDA approved the first drug, resmetirom, for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. Reliable, validated biomarkers that can replace histology for patient selection and primary end points in MASH trials will greatly accelerate the drug development process. Additionally, noninvasive tests that can reliably determine treatment response or predict response to therapy are warranted. Sustained efforts are required to combat the burden of MASLD by tackling metabolic risk factors, improving risk stratification and linkage to care, and increasing access to therapeutic agents and non-pharmaceutical interventions.
引用
收藏
页数:25
相关论文
共 188 条
  • [1] Younossi Z.M., Et al., The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review, Hepatology, 77, pp. 1335-1347, (2023)
  • [2] Tacke F., Et al., EASL–EASD–EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD), J. Hepatol, 81, pp. 492-542, (2023)
  • [3] Rinella M.E., Et al., AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease, Hepatology, 77, pp. 1797-1835, (2023)
  • [4] Brunt E.M., Neuschwander-Tetri B.A., Oliver D., Wehmeier K.R., Bacon B.R., Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens, Hum. Pathol, 35, pp. 1070-1082, (2004)
  • [5] Tan D.J.H., Et al., Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis, Lancet Oncol, 23, pp. 521-530, (2022)
  • [6] Papatheodoridi M., Et al., Health-related quality of life in patients with nonalcoholic fatty liver disease: a prospective multi-center UK study, Clin. Gastroenterol. Hepatol, 21, pp. 3107-3114.e3103, (2023)
  • [7] Younossi Z.M., Et al., Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD) registry, Clin. Gastroenterol. Hepatol, 20, pp. 2296-2306.e2296, (2022)
  • [8] Koh J.H., Et al., NASH is the leading cause of hepatocellular carcinoma in liver transplant candidates, Clin. Gastroenterol. Hepatol, 22, pp. 197-199.e193, (2024)
  • [9] Ward Z.J., Et al., Projected US state-level prevalence of adult obesity and severe obesity, N. Engl. J. Med, 381, pp. 2440-2450, (2019)
  • [10] Sun H., Et al., IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045, Diabetes Res. Clin. Pract, 183, (2022)